Drug Makers Gear Up For 2023-2024 COVID-19 Season With Subvariant Vaccines
Pfizer/BioNTech, Moderna, Novavax Work With Regulators
The companies are all preparing to make available vaccines targeted to Omicron XBB subvariants, with the expectation that demand in the US will be about 50 million to 100 million doses.
